A method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect

Details for Australian Patent Application No. 2006207998 (hide)

Owner Novartis Vaccines and Diagnostics Inc.

Inventors Vadevanter, Donald

Agent FB Rice

Pub. Number AU-A-2006207998

PCT Pub. Number WO2006/081429

Priority 60/647,477 27.01.05 US

Filing date 27 January 2006

Wipo publication date 3 August 2006

International Classifications

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

Event Publications

30 August 2007 PCT application entered the National Phase

  PCT publication WO2006/081429 Priority application(s): WO2006/081429

14 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006207999-Leader sequences for directing secretion of polypeptides and methods for production thereof

2006207991-Flowing electrolyte battery with electric potential neutralization